The New Normal: COVID-19 vaccines, myocarditis and hospitalization studies
News 12's Elizabeth Hashagen was joined today Dr. Daniel Griffin, the chief of the Division of Infectious Disease at ProHEALTH, to discuss COVID-19 vaccines.
Vaccine maker Novavax said today that its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said. All cases in the vaccine group were mild, meaning the vaccine was 100% percent effective against moderate to severe illness. Dr. Griffin talks about the vaccine in the video below:
The Centers for Disease Control and Prevention has scheduled an emergency meeting to discuss growing evidence that certain COVID-19 vaccines may be linked to myocarditis, a heart inflammation issue, in teens and young adults.
A study shows that virtually all hospitalized COVID-19 patients have one thing in common - they're unvaccinated. Early monoclonal antibody administration can reduce both hospitalizations and mortality in high-risk outpatients with COVID-19. Dr. Griffin talks about what he is seeing:
If most people with COVID-19 don't end up in the hospital, how many people get long COVID-19? Who is most at risk?